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E-mail address: mgkabir73@yahoo.com (G. Kabir).Aim and Background: Free IGF-1 and IGFBP-1 are associated with obesity which is one of the major fea-
tures of insulin resistance. But very few studies exist on free IGF-1 and IGFBP-1 in IGT subjects. The pres-
ent study was undertaken to investigate the association of free IGF-1 and IGFBP-1 with insulin sensitivity
in IGT subjects. Subjects and Methods: Ninety-one subjects with impaired glucose tolerance (IGT) were
studied along with age- sex- and BMI-matched sixty-one healthy Controls without family history of dia-
betes or prediabetes. Insulin, free IGF-1 and IGFBP-1 were measured by standard ELISA method. Insulin
secretory capacity (HOMA B) and insulin sensitivity (HOMA S) were calculated using fasting glucose and
fasting insulin by HOMA-CIGMA software. Results: Fasting free IGF-1 and IGFBP-1 levels were not signif-
icantly different among the study groups. In stepwise multiple regression analysis, when free IGF-1 was
considered as a dependent variable with other independent variables, model 1 (b = 0.352, p = 0.03),
model 2 (b = 0.355, p = 0.033) and model 5 (b = 0.378, p = 0.026) have shown signiﬁcant association
of fasting glucose with free IGF-1. Similarly when IGFBP-1 was considered as a dependent variable, model
4 (b = 0.865, p = 0.03) and model 5 (b = 0.1.07, p = 0.004) have shown negative association of fasting
glucose with IGFBP-1. In this analysis model 5 have also shown negative association of HOMA S with
IGFBP-1 (b = 1.015, p = 0.017). Conclusion: IGF1 and IGFBP-1 seems to be negatively associated with fast-
ing glucose in IGT subjects and insulin sensitivity (HOMA S) may also be negatively associated with
IGFBP-1 in IGT subjects.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Insulin, like growth factor-1 (IGF-1), is a multipotent growth
factor with important action on normal tissue growth and metab-
olism. In addition, IGF-1 has been suggested to have beneﬁcial ef-
fects on glucose homeostasis, due to its glucose lowering and
insulin sensitizing actions. Epidemiological studies suggest that
IGF-1 is also involved in the development of common cancer, ath-
erosclerosis and type 2 diabetes [1–4]. In several pathological
states, an impairment of IGF-1 action on glucose metabolism has
been recorded, along with insulin resistance [5–7]; however, it is
not known whether IGF-1 and insulin resistance are always associ-
ated and it is not clear whether resistance, when it does occur, af-
fects only glucose uptake and metabolism or protein metabolism
as well. Frystyk et al. (1999) have found that circulating fasting free
IGF-I is increasingly elevated with increasing obesity, whereasellitus. Published by Elsevier Ltd.
mistry & Molecular Biology,
h. Tel.: +8801711943681.
Oserum total IGF-I is normal. They have proposed that elevated ser-
um free IGF-I may be caused by insulin resistance inducing hyper-
insulinemia which suppress IGFBP-1 [8].
Although IGF-1 is structurally related to insulin, unlike insulin,
it circulates bound to speciﬁc proteins called IGF binding proteins
(IGFBPs) with variable afﬁnity [9]. IGFBP-1 levels have been shown
to be elevated in type 1 diabetes and in patients with insulin resis-
tance syndromes. Type 2 diabetes tends to have low serum IGFBP-1
levels. Patients with growth hormone deﬁciency tend to have ele-
vated IGFBP-1 levels [10]. Insulin inhibits the hepatic synthesis and
secretion of IGFBP-1 [11,12] and increases the portal concentra-
tions of insulin decrease serum levels of IGFBP-1 in obese subjects
[8]. Frystyk et al., 1999 [8] have shown that simple obesity was
associated with reduced levels of IGFBP-1 when compared to lean
control and obese type 2 diabetes.
Free IGF-1 and IGFBP-1 have been well studied in type 1 dia-
betic subjects and also in type 2 diabetic subjects with higher
BMI (BMI > 30). In developing countries like Bangladesh, type 2
diabetic patients mostly possess lower to normal BMI, and no
reports of free IGF-1 and IGFBP-1 exist in this physiologicalpen access under CC BY-NC-ND license.
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factor for insulin resistance. The variation in serum concentrations
of IGF-1 and IGFBP-1 occurs due to racial variation. Moreover Im-
paired glucose tolerance (IGT), which is also known as the defect
of insulin resistance, is not well explored in regard to free IGF-1
and IGFBP-1 issues, which may help to know the early mechanisms
of the onset of insulin resistance and the development of diabetes.
The present study has been undertaken to explore the association
of insulin resistance with free IGF-1 and IGFBP-1 in IGT subjects.
2. Materials and methods
This cross-sectional observational study was conducted in Ban-
gladesh Institute of Research and Rehabilitation in Diabetes, Endo-
crine and Metabolic Disorders (BIRDEM), Dhaka. A group of 91
impaired glucose tolerant (IGT) subjects were selected purposively
from the Out-Patient Department (OPD) of BIRDEM, along with a
group of 61 age-, sex- and BMI-matched healthy subjects without
family history of diabetes as Controls from the friend circle of the
IGT subjects considering the same socio-economic status. Written
consent was taken from all the volunteers; clinical examinationsTable 1
Clinical characteristics of the study subjects.
Variable Control (n = 61) IGT (n = 91)
Age (yrs) 36 ± 6 43 ± 9
BMI (kg/m2) 25.4 ± 3.8 26.3 ± 4.0
WHR 0.91 ± 0.05 0.92 ± 0.05
MUAC (mm) 298 ± 27 303 ± 30
Triceps (mm) 14.6 ± 5.0 15.3 ± 5.4
Systolic blood pressure (mmHg) 115 ± 9 122 ± 17
Diastolic blood pressure (mmHg) 77 ± 9 82 ± 9*
Fasting glucose (mmol/l) 5.2 ± 0.5 5.7 ± 0.6*
Postprandial glucose (mmol/l) 5.9 ± 1.7 9.2 ± 1.3*
Results are expressed as M ± SD.
* p < 0.05, signiﬁcantly different compared to controls when using Student’s ‘t’
test.
Table 2
Serum insulinemic, lipid proﬁle, IGF-1 and IGFBP-1 status of the study subjects.
Variables Control (n = 61) IGT (n = 91)
Fasting Insulin (pmol/l) 51.7 (7.8–155.9) 67.7 (6.9–237.6)*
HOMA B 99 (21–187) 95(26–278)
HOMA S 86 (29–554) 66 (20–661)*
Triglyceride (mg/dl) 136 (52–408) 150 (50–491)
Cholesterol (mg/dl) 192 (90–261) 194 (105–298)
HDL-cholesterol (mg/dl) 30 (13–59) 30 (18–54)
LDL-cholesterol (mg/dl) 125 (46–203) 127 (63–239)
Free IGF-1 (pg/ml) 118.2 (39.4–486.1) 118.2 (19.9–465.9)
IGFBP-1 (ng/ml) 11.5 (1.1–83.97) 13.8 (1.6–68.1)
HOMA%B = B cell function assessed by homeostasis model assessment; HOMA%S =
insulin sensitivity assessed by homeostasis model assessment; Free IGF-1 = free
insulin like growth factor-1 and IGFBP-1 = insulin like growth factor binding pro-
tein-1.
* p < 0.05, signiﬁcantly different compared to controls when using Student’s ‘t’
test.
Table 3
Correlation of serum free IGF-1 and IGFBP-1 with different variables among the study gro
Group BMI F_G F_
Control Free IGF-1 r 0.078 0.116
p 0.709 0.582
IGFBP-1 r 0.192 0.16 
p 0.197 0.275
IGT Free IGF-1 r 0.240 0.337
p 0.142 0.025
IGFBP-1 r 0.056 0.121 
p 0.685 0.380
Data are expressed as correlation coefﬁcient (Paerson’s rho) r values and p = level of sigwere undertaken by a registered physician using a predesigned
questionnaire. Anthropometric measurements were taken using
standard methods. Subjects were requested to come on a pre-
scheduled morning, after overnight fasting for the fasting blood
sample; subjects were then given 75 gm anhydrous glucose dis-
solved in 250 ml water. Blood was taken at fasting conditions
and 2 h after glucose loading. Serum glucose, cholesterol, triglycer-
ide and HDL were determined by the enzymatic colorimetric meth-
od, using commercial kits (Randox Laboratories Ltd., UK). The LDL
cholesterol in serum was calculated by using the formula: LDL-
cholesterol = Total cholesterol  (TG/5 + HDL-cholesterol). Serum
insulin levels were determined by enzyme linked immunosorbent
assay (ELISA) method (Linco Research Inc., USA). Serum free IGF-1
and IGFBP-1 concentrations were measured by enzyme linked
immunosorbent assay (ELISA) method (Ray Biotech, USA). Insulin
secretory capacity (HOMA B) and insulin sensitivity (HOMA S)
were calculated from fasting glucose and fasting insulin using
HOMA-CIGMA software [13].2.1. Statistical analysis
Data were expressed as mean ± SD (standard deviation), median
(range) and/or percentage (%) as appropriate using SPSS (Statistical
Package for Social Science) software for Windows version 10 (SPSS
Inc., Chicago, Illinois, USA). The statistical signiﬁcance of the differ-
ences between the values was assessed by Student’s ‘t’ test or
Mann–Whitney U test (as appropriate). A two-tailed p value of
<0.05 was considered to be statistically signiﬁcant.3. Results and observations
3.1. Clinical characteristics of the study subjects
Anthropometric measurements (BMI, WHR, MUAC, Triceps)
showed no difference I in controls and IGT subjects. Diastolic blood
pressure (mmHg) was signiﬁcantly (p = 0.007) higher in IGT sub-
jects compared to that of Controls (Table 1).3.2. Insulinimic status of the study subjects
Fasting serum insulin level was signiﬁcantly higher in IGT
(p = 0.004) compared to that of Controls. Insulin sensitivity (HOMA
S) was signiﬁcantly lower in IGT subjects (p = 0.001) compared to
that of Controls. Fasting serum free IGF-1 level and IGFBP-1 level
of IGT subjects showed no signiﬁcant difference compared to that
of Controls (Table 2).3.3. Bivariate correlation
Pearson’s correlation analysis has shown a signiﬁcant associa-
tion of fasting serum glucose with free IGF-1 (r = 0.337,
p = 0.025) but not with IGFBP-1 (Table 3).ups.
INS TG CHOL HOMA-B% HOMA-S%
0.099 0.295 0.086 -0.056 -0.106
0.639 0.152 0.683 0.789 0.614
0.186 0.227 0.043 0.062 0.29
0.205 0.120 0.773 0.676 0.153
0.053 0.097 0.168 0.180 0.044
0.749 0.555 0.306 0.275 0.791
0.210 0.202 0.005 0.157 0.218
0.124 0.138 0.974 0.253 0.111
niﬁcance.
Table 4
Stepwise Multiple regression analysis of free IGF-1 (dependent variable) in IGT subjects.
Variables Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
b p b p b p b p b p b p b p
F_GLU 0.352 0.030 0.355 0.033 0.321 0.058 0.318 0.062 0.378 0.026 0.051 0.892 0.131 0.734
TG 0.019 0.904 0.071 0.677 0.085 0.621 0.014 0.936 0.007 0.968 0.002 0.991
T_CHOL 0.167 0.339 0.163 0.353 0.276 0.128 0.291 0.107 0.306 0.092
F_INS 0122 0.455 0.637 0.141 1.110 0.056 0.967 0.104
HOMA S% 0.814 0.062 0.664 0.136 0.519 0.265
HOMA B% 0.773 0.212 0.802 0.197
BMI 0.173 0.325
R2 0.100 0.074 0.073 0.061 0.133 0.149 0.149
b stands for standardized regression coefﬁcients. R2 for adjusted R square (Multiple coefﬁcient of determination).
Table 5
Stepwise multiple regression analysis of IGFBP-1 (dependent variable) in IGT subjects.
Variables Model 1 Model 2 Model 3 Model 4 Model 5
b p b p b p b p b p
HOMA S% 0.145 0.392 0.200 0.414 0.188 0.643 0.587 0.170 1.015 0.017
HOMA B% 0.077 0.751 0.267 0.359 1.014 0.115 1.084 0.063
F_INS 0.577 0.237 0.065 0.904 0.363 0.473
F_GLU 0.865 0.030 1.070 0.004
BMI 0.477 0.006
R2 0.007 0.033 0.020 0.094 0.270
b stands for standardized regression coefﬁcients. R2 for adjusted R square (Multiple coefﬁcient of determination).
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In stepwise multiple regression analysis, when free IGF-1 was
considered as a dependent variable with other independent
variables, model 1 (b = 0.352, p = 0.03), model 2 (b = 0.355,
p = 0.033) and model 5 (b = 0.378, p = 0.026) have shown a signif-
icant association of fasting glucose with free IGF-1 (Table 4).
Similarly when IGFBP-1 was considered as a dependent vari-
able, model 4 (b = 0.865, p = 0.03) and model 5 (b = 0.1.07,
p = 0.004) have shown a negative association of fasting glucose
with IGFBP-1 (Table 5). In this analysis model 5 has also shown a
negative association of HOMA S with IGFBP-1 (b = 1.015,
p = 0.017).4. Discussion
It has been documented that free IGF-1 and IGFBP-1 are associ-
ated with type1 diabetes, as well as with obesity [14]. Studies on
obese type 2 diabetic subjects have shown an increasing tendency
of free IGF-1 and a decreasing tendency of IGFBP-1. Studies on ob-
ese IGT subjects have also claimed similar results. Unfortunately,
however, no studies exist on IGT with lower to normal BMI, which
mostly dominates in the developing countries like Bangladesh.
In this study the median (range) value of serum free IGF-1 (pg/
ml) in healthy subjects was 118 (39–486). A study of Danish pop-
ulation has shown that free IGF-1 is signiﬁcantly higher in obese
healthy subjects compared to lean healthy subjects [14]. The pres-
ent data show that Bangladeshi subjects have much lower levels of
free IGF-1 than that of the European population. A study of Ban-
gladeshi children aged 5–6 yrs, irrespective of gender, has shown
that total IGF-1 concentration level is much lower than that of
European children aged 3–6 yrs [15]. Another study in United
States based on age-adjusted Asian, African–American and Cauca-
sian population have shown that Asian population have signiﬁ-
cantly lower IGF-1 than Caucasians and African–Americans,
which indicates that IGF-1 has considerable racial variations [16].In the present study, the serum level of free IGF-1 was not sig-
niﬁcantly higher in IGT subjects compared to healthy Controls. In a
study by Frystyk et al. (1999), it has been shown that the levels of
free IGF-1 were increased in obese controls (BMI, 31.6 ± 0.7) com-
pared to lean controls (BMI, 22.8 ± 0.2), but in obese type 2 diabe-
tes (BMI, 32.3 ± 0.8) the levels of free IGF-1 did not differ
signiﬁcantly from either lean or obese controls [8]. A study on
the Korean population has also shown that free IGF-1 concentra-
tions were signiﬁcantly elevated in obese subjects (free IGF-1.
1.46 ± 1.1 lg/l; BMI 30 ± 2.5) when compared to controls (free
IGF-1. 0.91 ± 0.9 lg/l; BMI. 21.3 ± 1.4). There is an increasing ten-
dency for free IGF-1 in IGT (140 pg/ml) subjects than those of con-
trols (96 pg/ml) [9]. No studies have so far looked at free IGF-1 in
IGT or any other prediabetic subject.
In this study the values of serum IGFBP-1 had no signiﬁcant dif-
ference in IGT subjects, compared to controls. Similar values of
IGFBP-1 were found in control subjects with a normal BMI in the
Korean and Danish population [9,14]. In these studies they have
shown that obese people have signiﬁcantly lower values of
IGFBP-1 compared to lean controls and obese type 2 diabetic sub-
jects. Another study done in the USA has shown that IGFBP-1 in
type 1 diabetes was signiﬁcantly higher compared to healthy con-
trols and type 2 diabetic subjects [17].
Free IGF-1 was signiﬁcantly (r = 0.337, p = 0.025) associated
with fasting serum glucose in simple Pearson’s correlation which
is also reﬂected in stepwise multiple regression where both free
IGF-1 (model 1, 2 and 5 in Table 4) and IGFBP-1 (model 4 and 5
in Table 5) showed themselves to be negatively associated with
fasting serum glucose. HOMA S in stepwise multiple regressions
have also been shown to be signiﬁcantly associated with IGFBP-1
(model 5 in Table 5). Previous studies [9,14] documented that
obesity tends to lower the level of IGFBP-1, and in general, it is ac-
cepted that obesity is associated with hyperglycemia, so hypergly-
cemia may lower IGFBP-1 or vice versa. In this study although the
studied subjects were not highly obese, this idea strongly follows,
and BMI in stepwise multiple regression analysis has shown signif-
icantly to be associated with IGFBP-1 (model 5 in Table 5).
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IGF1 and IGFBP-1 seem to be negatively associated with fasting
glucose in IGT subjects and insulin sensitivity (HOMA S) may also
be negatively associated with IGFBP-1 in IGT subjects.Acknowledgement
Authors greatly acknowledge the Diabetic Association of
Bangladesh and International Program in the Chemical Sciences
(IPICS), Uppsala University, Sweden for the ﬁnancial support of this
study.References
[1] Jan Frystyk. Free insulin-like growth factors – measurements and relationships
to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res
2004;14(5):337–75.
[2] Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects on insulin
like growth factors on tumorigenesis, neoplastic growth. Endocr. Rev
2000;21:215–44.
[3] Vaessen N, Heutink P, Janseen JA, Witteman JC, Testers L, Hofman A, et al. A
polymorphism in the gene for IGF-1; functional properties and risk for type 2
diabetes and myocardial infraction. Diabetes 2001;50:637–42.
[4] Moschos SJ, Mantzoros CS. The role of IGF system in cancer: from basic to
clinical studies and clinical applications. Oncology 2002;63:317–32.
[5] Sowell MO, Robinson KA, Buse MG. Phenylarsine oxide and denervation
effects on hormone-stimulated glucose transport. Am J Physiol 1988;255:
E159–65.[6] Dohm GL, Elton CW, Raju MS, Mooney ND, Dimarchi R, Pories WJ, et al. IGF-I
stimulated glucose transport in human skeletal muscle and IGF-I resistance in
obesity and NIDDM. Diabetes 1990;39:1028–32.
[7] Sherwin RS, Greenawalt K, Shulman GI. Simultaneous in-sulin-like growth
factor I and insulin resistance in obese zucker rats. Diabetes 1992;41:691–7.
[8] Frystyk J, Vestbo E, SkjÒrbÒk C, Mogensen CE, Èrskov H. Free insulin-like
growth factors in human obesity. Metabolism 1995;44(Suppl 4):37–44.
[9] Nam SY, Lee EJ, Kim KR. Effect of obesity on total and free insulin-like growth
factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2,
IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord
1997;21:355–9.
[10] Hills FA, Gunn LK, Hardiman. ‘‘IGFBP-1 in the placenta, membranes and fetal
circulation: levels at term and preterm delivery”. Early Hum Dev
1996;44(1):71–6.
[11] Brismar K, Fernqvist Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic
production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3,
and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab
1994;79:872–8.
[12] Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth
factor-binding protein-1. Proc Soc Exp Biol Med 1993;204(1):4–29.
[13] Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment
(HOMA) evaluation uses the computer program. Diabetes Care
1998;21:2191–2.
[14] Frystyk J, Skjñrbñk C, Vestbo E, Fisker S, érskov H. Circulating levels of free
insulin-like growth factors in obese subjects: the impact of type 2 diabetes.
Diabetes Metab Res Rev 1999;15:314–22.
[15] Burtis CA, Ashwood ER, Bruns DE Tietz. Textbook of Clinical chemistry and
Molecular diagnostics. Fourth edition. (Elsevier) 2006, p. 1971–75.
[16] Elizabeth A. Platz,2 Michael N. Pollak, Eric B. Rimm, Noreen Majeed, Yuzhen
Tao, Walter C. Willett, et al. Racial variation in insulin-like growth factor-1 and
binding protein-3concentrations in middle-aged men. Cancer, Epidemiol
Biomarkers Prevention 1999;8:1107–1110. .
[17] Jehle PM, Jehle DR, Mohan S, Bohm BO. Serum levels of insulin-like growth
factor system components and relationship to bone metabolism in type 1 and
type 2 diabetes mellitus patients. J Endocrinol 1998;159(2):297–306.
